alendronate has been researched along with Femoral Fractures in 109 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Femoral Fractures: Fractures of the femur.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Long-term alendronate therapy may lead to atypical femoral fractures in a very few patients." | 7.79 | Discontinuation of alendronate and administration of bone-forming agents after surgical nailing may promote union of atypical femoral fractures in patients on long-term alendronate therapy. ( Fong, YC; Hsu, CJ; Hsu, HC; Lin, TL; Tsai, CH; Wang, SJ, 2013) |
| "A paradoxical association between long-term alendronate therapy and low-energy subtrochanteric femoral fractures has been recently recognized." | 7.76 | Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features. ( Capeci, C; Chan, K; Chan, SS; Rosenberg, ZS, 2010) |
| " Recent reports have demonstrated the association between long-term alendronate therapy with low-energy subtrochanteric fracture or diaphyseal femoral fractures in a small number of patients." | 7.76 | Bilateral atypical femoral fractures after long-term alendronate therapy: a case report. ( Bamrungsong, T; Pongchaiyakul, C, 2010) |
| "Several recent medical articles have described multiple cases of unusual low-impact subtrochanteric stress fractures or completed fractures of the femur in patients who have been on the bisphosphonate alendronate for several years for osteoporosis or osteopenia." | 7.75 | Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. ( Schneider, JP, 2009) |
| "Seven patients who sustained low-energy bilateral subtrochanteric or diaphyseal femoral fractures while on long-term alendronate therapy were identified." | 7.75 | Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. ( Capeci, CM; Tejwani, NC, 2009) |
| " At the end of the osteoporosis development period, MP rats were randomized to receive: vehicle (n= 7), genistein aglycone (5 mg x kg(-1) s." | 7.75 | Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate. ( Altavilla, D; Armbruster, MA; Bitto, A; Burnett, BP; Di Stefano, V; Irrera, N; Levy, RM; Marini, H; Minutoli, L; Polito, F; Squadrito, F, 2009) |
| " The current treatment for preventing and treating osteoporotic fractures is the use of antiresorptive drugs such as bisphosphonates (BPs) and denosumab, but unfortunately, their long-term use, especially with alendronate and ibandronate, has been associated with increased risk of atypical femoral fractures (AFFs); femoral diaphyseal fractures distal to the lesser trochanter but proximal to the supracondylar flare." | 5.22 | Effects of bisphosphonates on appendicular fracture repair in rodents. ( Hadjiargyrou, M, 2022) |
| " The fractures were associated with 6 years of oral alendronate treatment immediately followed by subcutaneous denosumab therapy and later teriparatide therapy for osteoporosis." | 5.01 | Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide. ( Poole, K; Sano, H; Tan, J, 2019) |
| "Of the eight patients, who sustained atypical femoral fractures, six were on alendronate and two were on zoledronate therapy before the fractures." | 4.90 | Predictors of atypical femoral fractures during long term bisphosphonate therapy: a case series & review of literature. ( Bhadada, SK; Bhansali, A; Dhiman, V; Mithal, A; Muthukrishnan, J; Sharma, DC; Sridhar, S, 2014) |
| " The patient had been followed-up for 15 years because of osteoporosis and administrated alendronate and ibandronate treatment for 10 years." | 3.83 | Atypical femoral fracture following zoledronic acid treatment. ( Ataoğlu, B; Berkay, AF; Eren, TK; Kaptan, AY; Yapar, AE, 2016) |
| " To determine the skeletal safety and efficacy of long term (≥10 years) alendronate use in patients with osteoporosis." | 3.83 | Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. ( Abrahamsen, B; Eastell, R; Eiken, P; Prieto-Alhambra, D, 2016) |
| "Until definite evidence is available, alendronate treatment in patients with osteoporosis is not now prohibited by the healthcare authorities, probably because its beneficial influence outweighs the adverse effects." | 3.81 | Low-energy femoral shaft fractures after long-term alendronate therapy: report of seven cases. ( Ballas, EG; Karamanis, E; Kokkalis, ZT; Koulalis, D; Mastrokalos, D; Mavrogenis, AF; Mitsiokapa, E; Papagelopoulos, PJ, 2015) |
| " We retrospectively reviewed the medical records of 45 consecutive AFFs in 34 Japanese patients who had received oral bisphosphonates (alendronate or risedronate) for osteoporosis before AFF and had been followed for ≥12 months (range, 12-90 months)." | 3.81 | Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide. ( Aizawa, T; Ando, S; Aonuma, H; Kasukawa, Y; Maekawa, S; Miyakoshi, N; Sasaki, H; Sasaki, S; Shimada, Y; Tsuchie, H, 2015) |
| "We report a 55-year-old woman who suffered atypical subtrochanteric femoral fractures (ASFFs) after 4 years of exposure to alendronate and then zolendronate given for "osteoporosis." | 3.78 | "Atypical femoral fractures" during bisphosphonate exposure in adult hypophosphatasia. ( Coburn, SP; Ericson, KL; Mumm, S; Sutton, RA; Whyte, MP, 2012) |
| "A paradoxical association between long-term alendronate therapy and low-energy subtrochanteric femoral fractures has been recently recognized." | 3.76 | Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features. ( Capeci, C; Chan, K; Chan, SS; Rosenberg, ZS, 2010) |
| " Recent reports have demonstrated the association between long-term alendronate therapy with low-energy subtrochanteric fracture or diaphyseal femoral fractures in a small number of patients." | 3.76 | Bilateral atypical femoral fractures after long-term alendronate therapy: a case report. ( Bamrungsong, T; Pongchaiyakul, C, 2010) |
| " At the end of the osteoporosis development period, MP rats were randomized to receive: vehicle (n= 7), genistein aglycone (5 mg x kg(-1) s." | 3.75 | Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate. ( Altavilla, D; Armbruster, MA; Bitto, A; Burnett, BP; Di Stefano, V; Irrera, N; Levy, RM; Marini, H; Minutoli, L; Polito, F; Squadrito, F, 2009) |
| "Several recent medical articles have described multiple cases of unusual low-impact subtrochanteric stress fractures or completed fractures of the femur in patients who have been on the bisphosphonate alendronate for several years for osteoporosis or osteopenia." | 3.75 | Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. ( Schneider, JP, 2009) |
| "Seven patients who sustained low-energy bilateral subtrochanteric or diaphyseal femoral fractures while on long-term alendronate therapy were identified." | 3.75 | Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. ( Capeci, CM; Tejwani, NC, 2009) |
| " The recommendations for the management and care of patients who are on long-term use of alendronate (bisphosphonates) are summarized." | 2.46 | Risk of atypical femoral fracture with long-term use of alendronate (bisphosphonates) : a systemic review of literature. ( Agarwal, G; Agarwal, PK; Agarwal, S; Bansal, A; Gupta, P, 2010) |
| "She had been treated for postmenopausal osteoporosis with 70 mg of alendronate weekly for 2 years." | 1.91 | A Case Report of Oral Bisphosphonate Treatment for Osteoporosis Leading to Atypical Femoral Fracture and Pathologic Mandibular Fracture. ( Fernandes, TL; Franco, GCN; Jitumori, C; Viezzer Fernandes, B, 2023) |
| "These images were compatible with stress fractures of both femurs." | 1.46 | Surgical treatment of bilateral femoral stress fractures related with long-term alendronate therapy. ( Ataoğlu, MB; Çetinkaya, M; Kanatlı, U; Özer, M; Topçu, HN, 2017) |
| " We assumed that both of the fractures were associated with the long-term use of alendronate." | 1.43 | Localized cortical thickening of the femoral diaphysis captured on an X-ray before alendronate therapy in two cases of atypical femoral fracture. ( Iizuka, H; Iizuka, Y; Omodaka, T; Takagishi, K; Takechi, R, 2016) |
| "The authors describe a femoral pseudoarthrosis of an atypical fracture treated with intramedullary nailing in a female after prolonged alendronate therapy." | 1.39 | Pseudoarthrosis in atypical femoral fracture: case report. ( Bottai, V; De Paola, G; Dell'Osso, G; Ghilardi, M; Giannotti, S; Guido, G, 2013) |
| "Patients with a diagnosis of postmenopausal osteoporosis, bisphosphonate usage of at least 5 years and prodromal pain prior to fracture were included the study." | 1.39 | Bilateral low-energy sequential femoral shaft fractures in patients on long-term bisphosphonate therapy. ( Çakmak, S; Erdik, B; Keklikçi, K; Mahiroğulları, M; Rodop, O; Sarı, E, 2013) |
| " During her most recent gynecology visit, she expressed concern about unusual femoral fractures being linked to long-term use of alendronate." | 1.39 | Menopause practitioner perspective on the American Society of Bone and Mineral Research Task Force report on atypical femoral fracture. ( Ettinger, B; Schnatz, PF; Stuenkel, CA, 2013) |
| "Bisphosphonate-associated stress fractures and completed fractures are unique, possessing subtle characteristic radiographic features." | 1.38 | Femoral stress fractures associated with long-term bisphosphonate treatment. ( Carter, CJ; Emory, CL; Ward, WG; Wilson, SC, 2012) |
| "Hip fractures are important because they are associated with an increased rate of death, substantial morbidity, enormous costs, and devastating effects on independence and quality of life." | 1.37 | Bisphosphonate-related subtrochanteric femoral fractures. ( Baxter, M; Gunawardena, I; Rasekh, Y, 2011) |
| "Alendronate-treated patients are at higher risk of hip and subtrochanteric/diaphyseal fracture than matched control subjects." | 1.36 | Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. ( Abrahamsen, B; Eastell, R; Eiken, P, 2010) |
| "Bisphosphonates are widely used for treatment of postmenopausal osteoporosis." | 1.35 | Case reports: two femoral insufficiency fractures after long-term alendronate therapy. ( Sayed-Noor, AS; Sjödén, GO, 2009) |
| " We also sought evidence of a dose-response relationship, where high adherence to or long-term use of aln led to more atypical femur fractures." | 1.35 | Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. ( Abrahamsen, B; Eastell, R; Eiken, P, 2009) |
| "The arterial hypertension is a disorder characterized by relevant alterations in the bone tissue." | 1.35 | Local action of sodium alendronate in bone repair of spontaneously hypertensive rat (SHR). ( Chin, CM; Faig-Leite, H; Fernandes, RG; Nobre, MD, 2008) |
| "These insufficiency fractures could possibly have developed from the over suppression of bone turnover from prolonged alendronate therapy, in keeping with recently published evidence." | 1.35 | An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? ( Goh, SK; Howe, TS; Koh, JS; Kwek, EB; Png, MA, 2008) |
| " We believe that this finding is important and indicates the need for caution in the long-term use of alendronate in the treatment of osteoporosis." | 1.34 | Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. ( Chua, DT; Chua, SY; Goh, SK; Howe, TS; Koh, JS; Wong, MK; Yang, KY, 2007) |
| "Up to 80-90% of patients with treatment-requiring osteoporosis are not receiving specific treatment." | 1.31 | [Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate]. ( Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 26 (23.85) | 29.6817 |
| 2010's | 78 (71.56) | 24.3611 |
| 2020's | 5 (4.59) | 2.80 |
| Authors | Studies |
|---|---|
| Hadjiargyrou, M | 1 |
| Fernandes, TL | 1 |
| Viezzer Fernandes, B | 1 |
| Jitumori, C | 1 |
| Franco, GCN | 1 |
| Fung, E | 1 |
| Yamamoto, N | 1 |
| Dan'ura, T | 1 |
| Noda, T | 1 |
| Ozaki, T | 1 |
| Kondo, N | 1 |
| Miyasaka, D | 1 |
| Watanabe, Y | 1 |
| Sato, H | 1 |
| Kanda, T | 1 |
| Endo, N | 1 |
| Barak, U | 1 |
| Rosenthal, Y | 1 |
| Arami, A | 1 |
| Kosashvili, Y | 1 |
| Velkes, S | 1 |
| Peake, C | 1 |
| Trompeter, A | 1 |
| Ayyoub, S | 1 |
| Coyne, C | 1 |
| Leclerc, JT | 1 |
| Michou, L | 1 |
| Vaillancourt, F | 1 |
| Pelet, S | 1 |
| Simonyan, D | 1 |
| Belzile, EL | 1 |
| Tan, J | 1 |
| Sano, H | 1 |
| Poole, K | 1 |
| Fu, LJ | 1 |
| Tang, TT | 1 |
| Hao, YQ | 1 |
| Dai, KR | 1 |
| Chiu, WY | 1 |
| Lee, JJ | 1 |
| Tsai, KS | 1 |
| Chatterjee, S | 1 |
| Giannotti, S | 1 |
| Bottai, V | 1 |
| Dell'Osso, G | 1 |
| De Paola, G | 1 |
| Ghilardi, M | 1 |
| Guido, G | 1 |
| Çakmak, S | 1 |
| Mahiroğulları, M | 1 |
| Keklikçi, K | 1 |
| Sarı, E | 1 |
| Erdik, B | 1 |
| Rodop, O | 1 |
| Tarazona-Santabalbina, FJ | 1 |
| Aguilella-Fernández, L | 1 |
| Ettinger, B | 1 |
| Stuenkel, CA | 1 |
| Schnatz, PF | 1 |
| Drampalos, E | 1 |
| Skarpas, G | 1 |
| Barbounakis, N | 1 |
| Michos, I | 1 |
| Thompson, RN | 1 |
| Armstrong, CL | 1 |
| Heyburn, G | 1 |
| Gopal, GK | 1 |
| Tam, KL | 1 |
| Krishnan, SP | 1 |
| Maddern, IL | 1 |
| Atik, OS | 2 |
| Oztürk, AM | 1 |
| Kunat, C | 1 |
| Cetinkaya, M | 2 |
| Kaptan, Y | 1 |
| Ballas, EG | 1 |
| Mavrogenis, AF | 1 |
| Karamanis, E | 1 |
| Kokkalis, ZT | 1 |
| Mitsiokapa, E | 1 |
| Koulalis, D | 1 |
| Mastrokalos, D | 1 |
| Papagelopoulos, PJ | 1 |
| O'Neill, BJ | 1 |
| O'hEireamhoin, S | 1 |
| Morrissey, DI | 1 |
| Keogh, P | 1 |
| Kharazmi, M | 1 |
| Hallberg, P | 1 |
| Warfvinge, G | 1 |
| Michaëlsson, K | 2 |
| Bhadada, SK | 1 |
| Sridhar, S | 1 |
| Muthukrishnan, J | 1 |
| Mithal, A | 1 |
| Sharma, DC | 1 |
| Bhansali, A | 1 |
| Dhiman, V | 1 |
| Miyakoshi, N | 1 |
| Aizawa, T | 1 |
| Sasaki, S | 1 |
| Ando, S | 1 |
| Maekawa, S | 1 |
| Aonuma, H | 1 |
| Tsuchie, H | 1 |
| Sasaki, H | 1 |
| Kasukawa, Y | 1 |
| Shimada, Y | 1 |
| Miller, PD | 1 |
| McCarthy, EF | 1 |
| Özsoy, MH | 1 |
| Aksekili, MA | 1 |
| Kızılay, O | 1 |
| Dinçel, VE | 1 |
| Aydoğan, NH | 1 |
| Ozsoy, A | 1 |
| Schilcher, J | 2 |
| Koeppen, V | 1 |
| Aspenberg, P | 2 |
| Roth, A | 1 |
| Beckmann, J | 1 |
| Smolenski, U | 1 |
| Fischer, A | 1 |
| Jäger, M | 1 |
| Tingart, M | 1 |
| Rader, C | 1 |
| Peters, KM | 1 |
| Reppenhagen, S | 1 |
| Nöth, U | 1 |
| Heiss, C | 1 |
| Maus, U | 1 |
| Koh, JH | 1 |
| Myong, JP | 1 |
| Jung, SM | 1 |
| Lee, J | 2 |
| Kwok, SK | 1 |
| Park, SH | 1 |
| Ju, JH | 1 |
| Ataoğlu, B | 1 |
| Kaptan, AY | 1 |
| Eren, TK | 1 |
| Yapar, AE | 1 |
| Berkay, AF | 1 |
| Hyodo, K | 1 |
| Nishino, T | 1 |
| Kamada, H | 1 |
| Nozawa, D | 1 |
| Mishima, H | 1 |
| Yamazaki, M | 1 |
| Yao, W | 1 |
| Lay, YE | 1 |
| Kot, A | 1 |
| Liu, R | 1 |
| Zhang, H | 1 |
| Chen, H | 1 |
| Lam, K | 1 |
| Lane, NE | 1 |
| Abrahamsen, B | 4 |
| Eiken, P | 3 |
| Prieto-Alhambra, D | 1 |
| Eastell, R | 4 |
| Iizuka, Y | 1 |
| Takechi, R | 1 |
| Iizuka, H | 1 |
| Omodaka, T | 1 |
| Takagishi, K | 1 |
| Bartl, R | 1 |
| Kanatlı, U | 1 |
| Ataoğlu, MB | 1 |
| Özer, M | 1 |
| Topçu, HN | 1 |
| Nobre, MD | 1 |
| Fernandes, RG | 1 |
| Chin, CM | 1 |
| Faig-Leite, H | 1 |
| Visekruna, M | 1 |
| Wilson, D | 1 |
| McKiernan, FE | 1 |
| Lee, P | 1 |
| Seibel, MJ | 2 |
| Gerstenfeld, LC | 1 |
| Sacks, DJ | 1 |
| Pelis, M | 1 |
| Mason, ZD | 1 |
| Graves, DT | 1 |
| Barrero, M | 1 |
| Ominsky, MS | 1 |
| Kostenuik, PJ | 1 |
| Morgan, EF | 1 |
| Einhorn, TA | 1 |
| Uveges, TE | 1 |
| Kozloff, KM | 1 |
| Ty, JM | 1 |
| Ledgard, F | 1 |
| Raggio, CL | 1 |
| Gronowicz, G | 1 |
| Goldstein, SA | 1 |
| Marini, JC | 1 |
| Sayed-Noor, AS | 1 |
| Sjödén, GO | 1 |
| Schneider, JP | 2 |
| Bitto, A | 1 |
| Burnett, BP | 1 |
| Polito, F | 1 |
| Levy, RM | 1 |
| Marini, H | 1 |
| Di Stefano, V | 1 |
| Irrera, N | 1 |
| Armbruster, MA | 1 |
| Minutoli, L | 1 |
| Altavilla, D | 1 |
| Squadrito, F | 1 |
| Burr, DB | 1 |
| Diab, T | 1 |
| Koivunemi, A | 1 |
| Koivunemi, M | 1 |
| Allen, MR | 1 |
| Somford, MP | 1 |
| Draijer, FW | 1 |
| Thomassen, BJ | 1 |
| Chavassieux, PM | 1 |
| Boivin, G | 1 |
| Papapoulos, SE | 1 |
| Harada, A | 1 |
| Ali, T | 1 |
| Jay, RH | 1 |
| Edwards, MH | 1 |
| McCrae, FC | 1 |
| Young-Min, SA | 1 |
| Agarwala, S | 1 |
| Shah, S | 1 |
| Joshi, VR | 1 |
| Ing-Lorenzini, K | 1 |
| Desmeules, J | 1 |
| Plachta, O | 1 |
| Suva, D | 1 |
| Dayer, P | 1 |
| Peter, R | 1 |
| Capeci, CM | 1 |
| Tejwani, NC | 1 |
| Compston, JE | 1 |
| Cermak, K | 1 |
| Shumelinsky, F | 1 |
| Alexiou, J | 1 |
| Gebhart, MJ | 1 |
| Saito, M | 1 |
| Shiraishi, A | 1 |
| Ito, M | 1 |
| Sakai, S | 1 |
| Hayakawa, N | 1 |
| Mihara, M | 1 |
| Marumo, K | 1 |
| Suluova, F | 1 |
| Görmeli, G | 1 |
| Yildirim, A | 1 |
| Ali, AKh | 1 |
| Black, DM | 2 |
| Kelly, MP | 1 |
| Genant, HK | 1 |
| Palermo, L | 1 |
| Bucci-Rechtweg, C | 1 |
| Cauley, J | 1 |
| Leung, PC | 1 |
| Boonen, S | 1 |
| Santora, A | 1 |
| de Papp, A | 1 |
| Bauer, DC | 1 |
| Shane, E | 1 |
| Lee, JK | 1 |
| Ahn, JK | 1 |
| Cha, HS | 1 |
| Koh, EM | 1 |
| Das De, S | 4 |
| Setiobudi, T | 2 |
| Shen, L | 1 |
| Girgis, CM | 1 |
| Sher, D | 1 |
| Chan, SS | 1 |
| Rosenberg, ZS | 1 |
| Chan, K | 1 |
| Capeci, C | 1 |
| Fahlgren, A | 1 |
| Bamrungsong, T | 1 |
| Pongchaiyakul, C | 1 |
| Ott, SM | 2 |
| Pozzi, S | 1 |
| Raje, N | 1 |
| Singer, FR | 1 |
| Agarwal, S | 2 |
| Gupta, P | 1 |
| Agarwal, PK | 1 |
| Agarwal, G | 1 |
| Bansal, A | 1 |
| Osugi, K | 1 |
| Miwa, S | 1 |
| Marukawa, S | 1 |
| Marukawa, K | 1 |
| Kawaguchi, Y | 1 |
| Nakato, S | 1 |
| Falkenberg, MP | 1 |
| Ng, YH | 1 |
| Gino, PD | 1 |
| Lingaraj, K | 1 |
| Gomberg, SJ | 1 |
| Wustrack, RL | 1 |
| Napoli, N | 1 |
| Arnaud, CD | 1 |
| Gunawardena, I | 1 |
| Baxter, M | 1 |
| Rasekh, Y | 1 |
| Wang, K | 1 |
| Moaveni, A | 1 |
| Dowrick, A | 1 |
| Liew, S | 1 |
| Haque, S | 1 |
| Siddiqui, G | 1 |
| Puah, KL | 1 |
| Tan, MH | 1 |
| Unnanuntana, A | 1 |
| Ashfaq, K | 1 |
| Ton, QV | 1 |
| Kleimeyer, JP | 1 |
| Lane, JM | 2 |
| Jain, SK | 1 |
| Roy, SP | 1 |
| Nagi, ON | 1 |
| Jamal, SA | 1 |
| Dion, N | 1 |
| Ste-Marie, LG | 1 |
| Ward, WG | 1 |
| Carter, CJ | 1 |
| Wilson, SC | 1 |
| Emory, CL | 1 |
| Mulgund, M | 1 |
| Beattie, KA | 1 |
| Anaspure, R | 1 |
| Matsos, M | 1 |
| Patel, A | 1 |
| Adachi, JD | 1 |
| Sutton, RA | 1 |
| Mumm, S | 1 |
| Coburn, SP | 1 |
| Ericson, KL | 1 |
| Whyte, MP | 1 |
| Pazianas, M | 1 |
| Wang, Y | 1 |
| Russell, RG | 1 |
| Vigorita, VJ | 1 |
| Silver, JS | 1 |
| Eisemon, EO | 1 |
| Lim, CT | 1 |
| Cross, MB | 1 |
| Nam, D | 1 |
| van der Meulen, MC | 1 |
| Bostrom, MP | 1 |
| Seraphim, A | 1 |
| Al-Hadithy, N | 1 |
| Mordecai, SC | 1 |
| Al-Nammari, S | 1 |
| Huang, HT | 1 |
| Kang, L | 1 |
| Huang, PJ | 2 |
| Fu, YC | 1 |
| Lin, SY | 1 |
| Hsieh, CH | 1 |
| Chen, JC | 1 |
| Cheng, YM | 2 |
| Chen, CH | 2 |
| Meier, RP | 1 |
| Ing Lorenzini, K | 1 |
| Uebelhart, B | 1 |
| Stern, R | 1 |
| Peter, RE | 1 |
| Rizzoli, R | 1 |
| Kao, CM | 1 |
| Chen, SJ | 1 |
| Zafeiris, CP | 1 |
| Stathopoulos, IP | 1 |
| Kourkoumelis, G | 1 |
| Gkikas, E | 1 |
| Lyritis, GP | 1 |
| Howe, TS | 3 |
| Ehrlich, GD | 1 |
| Erlich, G | 1 |
| Koh, JS | 3 |
| Ng, AC | 1 |
| Costerton, W | 1 |
| Lin, TL | 1 |
| Wang, SJ | 1 |
| Fong, YC | 1 |
| Hsu, CJ | 1 |
| Hsu, HC | 1 |
| Tsai, CH | 1 |
| Minne, HW | 1 |
| Pollähne, W | 1 |
| Pfeifer, M | 1 |
| Begerow, B | 1 |
| Hinz, C | 1 |
| Wong, P | 1 |
| Anpalahan, M | 1 |
| Roux, C | 1 |
| Briot, K | 1 |
| Dumarcet, N | 1 |
| Bourgoin, M | 1 |
| Chapurlat, R | 1 |
| Christin-Maitre, S | 1 |
| Cortet, B | 1 |
| Costagliola, D | 1 |
| Diebolt, V | 1 |
| Lacoin, F | 1 |
| Letombe, B | 1 |
| Oberlin, F | 1 |
| Orcel, P | 1 |
| Ravaud, P | 1 |
| Seret, P | 1 |
| Thomas, T | 1 |
| Vogel, JY | 1 |
| Barna, A | 1 |
| Nouyrigat, E | 1 |
| Veyries, ML | 1 |
| Yoldjian, I | 1 |
| Goh, SK | 2 |
| Yang, KY | 1 |
| Wong, MK | 1 |
| Chua, SY | 1 |
| Chua, DT | 1 |
| Cheung, RK | 1 |
| Leung, KK | 1 |
| Lee, KC | 1 |
| Chow, TC | 1 |
| Kwek, EB | 1 |
| Png, MA | 1 |
| Lenart, BA | 1 |
| Lorich, DG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Whole Exome Sequencing to Identify Genetic Predisposition to Atypical Femoral Fractures in Women Using Bisphosphonates for Osteoporosis[NCT02731040] | 38 participants (Actual) | Observational | 2016-04-30 | Completed | |||
| Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women[NCT02186600] | Phase 3 | 276 participants (Actual) | Interventional | 2015-02-01 | Completed | ||
| Genetic Analysis of Familial Cases of Premature Ovarian Failure[NCT01177891] | 110 participants (Actual) | Observational | 2010-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Bone mineral density is the gold standard for diagnosis of low bone mass and osteoporosis and will be measured at the spine using Dual Energy X-ray Absorptiometry (DXA). (NCT02186600)
Timeframe: Baseline,6, and 12 months
| Intervention | g/cm^2 (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 0.889 | .887 | 0.885 |
| Exercise | 0.886 | .878 | 0.885 |
| Risedronate | 0.892 | .907 | 0.911 |
"Change in Bone Strength Index (BSI) of the distal tibia based on randomization to Control, Risedronate, or Exercise group.~BSI (mg2/mm4) at the 4% tibial site will be measured using peripheral quantitative computed tomography (pQCT)." (NCT02186600)
Timeframe: Baseline, 6, and 12 months
| Intervention | mg^2/mm^4 (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 2098.7 | 2105.89 | 2107.2 |
| Exercise | 2001 | 1987.42 | 2009.2 |
| Risedronate | 1993.3 | 1997.32 | 2014.2 |
Bone turnover is the process of removing old bone (resorption by osteoclasts) and replacing it with new bone (formation by osteoblasts). Menopause results in a brief period (~5 years) of accelerated turnover with resorption far exceeding formation. In this study, resorption will be measured by Serum NTx. (NCT02186600)
Timeframe: Baseline, 6, 12 months
| Intervention | nanoMolar Bone Collagen Equivalents/L (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 13.99 | 12.16 | 12.36 |
| Exercise | 15.03 | 13.36 | 13.92 |
| Risedronate | 14.31 | 10.30 | 11.42 |
10 reviews available for alendronate and Femoral Fractures
| Article | Year |
|---|---|
Effects of bisphosphonates on appendicular fracture repair in rodents.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Denosumab; Diphosphonates; | 2022 |
Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide.
Topics: Absorptiometry, Photon; Adult; Alendronate; Bone Density; Denosumab; Dose-Response Relationship, Dru | 2019 |
Predictors of atypical femoral fractures during long term bisphosphonate therapy: a case series & review of literature.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Diphosphonates; Female; Femoral Fractures; Humans; | 2014 |
[Alendronate for treatment of osteoporoses].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Evidence-Based Medicine; Femoral Fractu | 2009 |
Alendronate-related femoral diaphysis fracture--what should be done to predict and prevent subsequent fracture of the contralateral side?
Topics: Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Fractures, Stress; Humans; | 2010 |
Metabolic bone disease: atypical femoral fractures.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biopsy; Bone and Bones | 2011 |
Risk of atypical femoral fracture with long-term use of alendronate (bisphosphonates) : a systemic review of literature.
Topics: Alendronate; Bone Density Conservation Agents; Femoral Fractures; Fractures, Stress; Humans | 2010 |
What is the optimal duration of bisphosphonate therapy?
Topics: Alendronate; Biomarkers; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Femoral F | 2011 |
Do bisphosphonates cause femoral insufficiency fractures?
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Femoral Fractures; Fractures | 2012 |
[Drug treatment of postmenopausal osteoporosis. What's New in 2006].
Topics: Absorptiometry, Photon; Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Body Mass Index; B | 2006 |
1 trial available for alendronate and Femoral Fractures
| Article | Year |
|---|---|
Prevalence and Characteristics of Atypical Periprosthetic Femoral Fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2019 |
98 other studies available for alendronate and Femoral Fractures
| Article | Year |
|---|---|
A Case Report of Oral Bisphosphonate Treatment for Osteoporosis Leading to Atypical Femoral Fracture and Pathologic Mandibular Fracture.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Fractures, | 2023 |
Early Alendronate Can Be Safe during Fracture Healing?
Topics: Alendronate; Bony Callus; Femoral Fractures; Fracture Healing; Humans | 2020 |
Non-traumatic Atypical Peri-implant Femoral Fracture at the Distal Screw after Short Femoral Nail Fixation for a Pertrochanteric Fracture.
Topics: Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Screws; Device Removal; Femal | 2020 |
Atypical femoral fracture associated with delayed union for which the cessation of alendronate and daily administration of teriparatide contributed to fracture healing: histopathological evidence of the enhancement in bone formation parameters.
Topics: Alendronate; Biopsy; Bone Density Conservation Agents; Disease Susceptibility; Female; Femoral Fract | 2020 |
[BISPHOSPHONATES AS A PREVENTATIVE TREATMENT FOR OSTEOPOROTIC HIP FRACTURES: A MIXED BLESSING].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Hip | 2017 |
Low-energy atypical femoral shaft and ipsilateral neck fracture: a rare association.
Topics: Aftercare; Aged; Alendronate; Bone Density Conservation Agents; Bone Plates; Bone Screws; Denosumab; | 2017 |
VISUAL VIGNETTE.
Topics: Alendronate; Bone Density Conservation Agents; Calcium Carbonate; Female; Femoral Fractures; Humans; | 2018 |
Long-term effects of alendronate on fracture healing and bone remodeling of femoral shaft in ovariectomized rats.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Remodeling; Disease Models, Animal; Dru | 2013 |
Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Huma | 2013 |
Atypical femoral fractures associated with long-term bisphosphonate use.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Huma | 2013 |
Pseudoarthrosis in atypical femoral fracture: case report.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Fracture Fixation, I | 2013 |
Bilateral low-energy sequential femoral shaft fractures in patients on long-term bisphosphonate therapy.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Early Diagn | 2013 |
Bisphosphonate long-term treatment related bilateral subtrochanteric femoral fracture. Can teriparatide be useful?
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Femur; Hum | 2013 |
Menopause practitioner perspective on the American Society of Bone and Mineral Research Task Force report on atypical femoral fracture.
Topics: Advisory Committees; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; | 2013 |
Atypical femoral fractures bilaterally in a patient receiving denosumab.
Topics: Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; D | 2014 |
Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Bone Density Conservation Age | 2014 |
Bisphosphonate-associated atypical subtrochanteric femur fractures in the older patient.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Femoral | 2014 |
Do atypical femoral fractures in patients with prolonged alendronate treatment heal?
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Calcium; Female; Femoral Fractures; Frac | 2014 |
Low-energy femoral shaft fractures after long-term alendronate therapy: report of seven cases.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diaphyses; | 2015 |
Implant failure caused by non-union of bisphosphonate-associated subtrochanteric femur fracture.
Topics: Alendronate; Bone Density Conservation Agents; Device Removal; Female; Femoral Fractures; Fracture F | 2014 |
Risk of atypical femoral fractures and osteonecrosis of the jaw associated with alendronate use compared with other oral bisphosphonates.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; D | 2014 |
Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femo | 2015 |
Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Femora | 2015 |
Femoral insufficiency fractures in the elderly - excessive medial femoral bowing complicates intramedullary nailing.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Female; Femoral Fractures; Femur; Fol | 2014 |
Risk of atypical femoral fracture during and after bisphosphonate use.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Cohort | 2015 |
[S3 guideline. Part 2: Non-Traumatic Avascular Femoral Head Necrosis in Adults - Untreated Course and Conservative Treatment].
Topics: Alendronate; Bone Density Conservation Agents; Evidence-Based Medicine; Female; Femoral Fractures; F | 2015 |
Atypical Femoral Fracture in Rheumatoid Arthritis Patients Treated With Bisphosphonates: A Nested Case-Control Study.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conserv | 2016 |
Atypical femoral fracture following zoledronic acid treatment.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Th | 2016 |
Location of fractures and the characteristics of patients with atypical femoral fractures: analyses of 38 Japanese cases.
Topics: Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density Conservation Agents; Bone Remodelin | 2017 |
Improved Mobilization of Exogenous Mesenchymal Stem Cells to Bone for Fracture Healing and Sex Difference.
Topics: Adipose Tissue; Alendronate; Animals; Bone Density; Bony Callus; Dipeptides; Female; Femoral Fractur | 2016 |
Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Cohort | 2016 |
Localized cortical thickening of the femoral diaphysis captured on an X-ray before alendronate therapy in two cases of atypical femoral fracture.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diagnosis, Differential; Dia | 2016 |
[Risk of atypical femur fractures does not increase among alen-dronate users].
Topics: Alendronate; Bone Density Conservation Agents; Femoral Fractures; Humans | 2016 |
Surgical treatment of bilateral femoral stress fractures related with long-term alendronate therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcium; Female; Femoral Fractures; Fractures, | 2017 |
Local action of sodium alendronate in bone repair of spontaneously hypertensive rat (SHR).
Topics: Alendronate; Analysis of Variance; Animals; Bone Density Conservation Agents; Bone Regeneration; Dis | 2008 |
Severely suppressed bone turnover and atypical skeletal fragility.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Female; Femoral | 2008 |
More on atypical fractures of the femoral diaphysis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Femora | 2008 |
Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing.
Topics: Alendronate; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomechanical Pheno | 2009 |
Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Calcification, Physiologic; Cartilage; | 2009 |
Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Cohort Studies; Cross-Sectional Studies; Denmark; Etidronic Ac | 2009 |
Case reports: two femoral insufficiency fractures after long-term alendronate therapy.
Topics: Aged; Alendronate; Arthroplasty, Replacement, Hip; Bone Density Conservation Agents; Bone Nails; Bon | 2009 |
Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Resorption; Drug Administration Schedule; | 2009 |
Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate.
Topics: Alendronate; Alkaline Phosphatase; Animals; Biomarkers; Bone Density; Bone Density Conservation Agen | 2009 |
Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Disease Models, Ani | 2009 |
Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility.
Topics: Aged; Alendronate; Arthritis, Rheumatoid; Biopsy; Bone Density; Bone Density Conservation Agents; Ca | 2009 |
Spontaneous femoral shaft fracture after long-term alendronate.
Topics: Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bony Callus; Female; Femoral Fract | 2009 |
The use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to eight years.
Topics: Administration, Oral; Adult; Alendronate; Bone Density Conservation Agents; Female; Femoral Fracture | 2009 |
Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Nails; Diphosphonates; | 2009 |
Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Humans; Middle Aged; | 2009 |
Bisphosphonates and atypical femoral fractures: a time for reflection.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Femoral | 2010 |
Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Nails; Female; Femoral Fractures; Fracture | 2010 |
Comparison of effects of alfacalcidol and alendronate on mechanical properties and bone collagen cross-links of callus in the fracture repair rat model.
Topics: Alendronate; Analysis of Variance; Animals; Biomechanical Phenomena; Bone Density; Bone Density Cons | 2010 |
Bisphosphonates: atypical fractures. Femur most often involved.
Topics: Alendronate; Diphosphonates; Femoral Fractures; Fractures, Bone; Humans | 2009 |
Insufficiency femoral fractures in patients undergoing prolonged alendronate therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Humans; Osteoporosis | 2010 |
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.
Topics: Alendronate; Bone Density Conservation Agents; Confidence Intervals; Diphosphonates; Female; Femoral | 2010 |
Evolving data about subtrochanteric fractures and bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Hip Fractu | 2010 |
Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium.
Topics: Absorptiometry, Photon; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Conservation Agents | 2009 |
Non-traumatic fracture of the femoral shaft in a patient taking long-term bisphosphonate therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Femora | 2011 |
A rational approach to management of alendronate-related subtrochanteric fractures.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density; Bone Density Conservation A | 2010 |
Atypical femoral fractures and bisphosphonate use.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Etidronic Acid; Female; Femoral Fractures; Hum | 2010 |
Thighbone fractures in women taking bisphosponate drugs.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femo | 2010 |
Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Fe | 2010 |
Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Frozen bone with remodelling at the crack.
Topics: Alendronate; Bone Density Conservation Agents; Bone Nails; Bone Resorption; Etidronic Acid; Female; | 2010 |
Bilateral atypical femoral fractures after long-term alendronate therapy: a case report.
Topics: Aged; Alendronate; Asian People; Bone Density Conservation Agents; Female; Femoral Fractures; Humans | 2010 |
Atraumatic bilateral femur fracture in long-term bisphosphonate use.
Topics: Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Fractures, Spontaneous; Hu | 2010 |
Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Fem | 2010 |
Bisphosphonates and atypical femoral fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Femoral Fractures; H | 2010 |
Diaphyseal femoral fatigue fracture associated with bisphosphonate therapy - 3 more cases.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Femoral Fractures; Frac | 2011 |
Atypical femoral fractures: a complication of prolonged bisphosphonate therapy?
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Femoral Fractures; Humans | 2011 |
Femoral shaft fractures in the elderly--role of prior bisphosphonate therapy.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Dose-Response | 2011 |
Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Female; Femoral Fractures; Fra | 2011 |
Bisphosphonate-related subtrochanteric femoral fractures.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Hip Fractures; Human | 2011 |
Alendronate-associated femoral insufficiency fractures and femoral stress reactions.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Nails; Female; Femoral | 2011 |
Ng YH, Gino PD, Lingaraj K, Das De S. Femoral shaft fracture in the elderly - role of prior bisphosphonate therapy.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Femoral Fractures; Humans | 2012 |
Bisphosphonate-associated atypical fracture of the femur: Spontaneous healing with drug holiday and re-appearance after resumed drug therapy with bilateral simultaneous displaced fractures--a case report.
Topics: Alendronate; Bone Density Conservation Agents; Bone Plates; Female; Femoral Fractures; Follow-Up Stu | 2011 |
The effect of long-term alendronate treatment on cortical thickness of the proximal femur.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Densitometr | 2012 |
Alendronate induced femur fracture complicated with secondary hyperparathyroidism.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Humans; Hyperparathy | 2011 |
Atypical femoral fractures and bone turnover.
Topics: Alendronate; Bone Remodeling; Diphosphonates; Female; Femoral Fractures; Femur; Fractures, Stress; H | 2011 |
Femoral stress fractures associated with long-term bisphosphonate treatment.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Female; Femoral Fractures; Fractures, Stress; | 2012 |
Atypical femoral fractures in patients taking longterm alendronate.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Humans; Middle Aged; | 2011 |
"Atypical femoral fractures" during bisphosphonate exposure in adult hypophosphatasia.
Topics: Alendronate; Diphosphonates; Female; Femoral Fractures; Humans; Hypophosphatasia; Imidazoles; Middle | 2012 |
Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Topics: Administration, Oral; Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedul | 2012 |
Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report.
Topics: Aged; Alendronate; Diphosphonates; Female; Femoral Fractures; Humans; Osteoclasts; Osteoporosis; Ost | 2012 |
Femoral canal obliteration secondary to prolonged alendronate use: a case report.
Topics: Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Fractur | 2012 |
A rare case of a bisphosphonate-induced peri-prosthetic femoral fracture.
Topics: Aged, 80 and over; Alendronate; Arthroplasty, Replacement, Hip; Bone Density Conservation Agents; Dr | 2012 |
Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report.
Topics: Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Fractures, Stress; Humans; | 2012 |
Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfecta--a case report.
Topics: Aged; Alendronate; Diphosphonates; Female; Femoral Fractures; Fracture Fixation, Intramedullary; Hum | 2012 |
Atypical femoral fracture after long-term alendronate treatment: report of a case evidenced with magnetic resonance imaging.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Humans; Magnetic Res | 2012 |
Simultaneous bilateral atypical femoral fractures after alendronate therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Humans; Osteoporosis | 2012 |
A case of an atypical femoral fracture associated with bacterial biofilm--pathogen or bystander?
Topics: Aged, 80 and over; Alendronate; Bifidobacteriales Infections; Bifidobacterium; Biofilms; Bone Densit | 2013 |
Discontinuation of alendronate and administration of bone-forming agents after surgical nailing may promote union of atypical femoral fractures in patients on long-term alendronate therapy.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Nails; Female; Femoral | 2013 |
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate].
Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents, | 2002 |
Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Bone Density Conservation Agents; Drug Therapy, C | 2006 |
Osteoporotic fractures and vitamin D deficiency.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractur | 2006 |
Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; F | 2007 |
Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Remodeling; Female; Femoral Fractures; Humans | 2007 |
An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Femora | 2008 |
Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Female; Fem | 2008 |